We hope you enjoyed a lazy summer weekend, and a welcome respite from last week's non-stop craziness. Meanwhile if you're looking for a dozen pages of in-depth advisory committee analysis, you'll find it in this week's Pink Sheet.
While you were dropping three out of four to the Cubs ...
- The New York Times explains the amyloid hypothesis, and takes a look at earlier intervention in Alzheimer's disease. Cameos from Elan's bapineuzumab and Bristol's BMS-708163.
- Also in the NYT, FDA has slapped Columbia University's renowned Kreitchman PET Center for allowing too many impurities in the radiotracers it uses and repeatedly violating FDA regs for four years.
- Reuters reads the Swiss papers so you don't have to: Novartis' Jiminez maintains offer to independent Alcon shareholders is "fair."
- Not all the advisory committee drama was last week: next up, Avastin. The SF Chronicle previews.
- The Washington Post unpacks the debate over consumer genetics testing regulation and previews this week's public hearing.
- Avandia gets Bad Science'd: "an ugly story about our collective medical incompetence."
- Data presented at the AIDS conference in Vienna suggests treating patients with cocktails of HIV drugs can prevent the spread of infection.